SG10201912366YA - Anti-cd3 antibody and molecules comprising the antibody - Google Patents

Anti-cd3 antibody and molecules comprising the antibody

Info

Publication number: SG10201912366YA
Authority: SG; Singapore
Prior art keywords: antibody; molecules
Prior art date: 2016-12-22

Application number

SG10201912366YA

Inventor

Tohru Takahashi

Chigusa Yoshimura

Shiho Kozuma

Kensuke Nakamura

Chikako Suzuki

Junya Ichikawa

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-22

Filing date

2017-12-21

Publication date

2020-02-27

2017-12-21 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2020-02-27 Publication of SG10201912366YA publication Critical patent/SG10201912366YA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

SG10201912366YA 2016-12-22 2017-12-21 Anti-cd3 antibody and molecules comprising the antibody SG10201912366YA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2016249148		2016-12-22

Publications (1)

Publication Number	Publication Date
SG10201912366YA true SG10201912366YA (en)	2020-02-27

Family

ID=62627719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201912366YA SG10201912366YA (en)	2016-12-22	2017-12-21	Anti-cd3 antibody and molecules comprising the antibody

Country Status (15)

Country	Link
US (2)	US11618785B2 (en)
EP (1)	EP3561057A4 (en)
JP (2)	JP7202185B2 (en)
KR (1)	KR20190121294A (en)
CN (1)	CN110431231B (en)
AU (1)	AU2017379382A1 (en)
BR (1)	BR112019012901A2 (en)
CA (1)	CA3048174A1 (en)
CO (1)	CO2019007823A2 (en)
IL (2)	IL267567B1 (en)
MX (1)	MX2019007347A (en)
PH (1)	PH12019501387A1 (en)
SG (1)	SG10201912366YA (en)
TW (1)	TW201829467A (en)
WO (1)	WO2018117237A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL267567B1 (en)	2016-12-22	2024-04-01	Daiichi Sankyo Co Ltd	Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
WO2019244107A1 (en) *	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
CN114174339A (en) *	2019-06-07	2022-03-11	阿迪马布有限责任公司	High affinity anti-CD 3 antibodies and methods of making and using the same
CA3175577A1 (en) *	2020-03-30	2021-10-07	Mie University	Bispecific antibody
CN114656562B (en) *	2020-12-23	2023-11-03	北京天广实生物技术股份有限公司	Antibodies that bind human and monkey CD3 and uses thereof
EP4317435A1 (en)	2021-03-29	2024-02-07	Daiichi Sankyo Company, Limited	Stable multispecific molecule and use thereof
WO2023061419A1 (en) *	2021-10-12	2023-04-20	Concept To Medicine Biotech Co., Ltd.	Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
WO2023169419A1 (en) *	2022-03-09	2023-09-14	Antengene (Hangzhou) Biologics Co., Ltd.	Novel anti-cd3 antibodies and uses thereof
WO2023183766A1 (en) *	2022-03-20	2023-09-28	Abcellera Biologics Inc.	Anti-cd3 antibodies and t-cell engagers and methods of use
WO2023178645A1 (en) *	2022-03-25	2023-09-28	嘉和生物药业有限公司	Cd3-targeting antibody and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992020791A1 (en)	1990-07-10	1992-11-26	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
DK0605522T3 (en)	1991-09-23	2000-01-17	Medical Res Council	Process for producing humanized antibodies
ES2227512T3 (en)	1991-12-02	2005-04-01	Medical Research Council	PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
JP3507073B2 (en)	1992-03-24	2004-03-15	ケンブリッジアンティボディーテクノロジーリミティド	Methods for producing members of a specific binding pair
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
EP0731842A1 (en)	1993-12-03	1996-09-18	Medical Research Council	Recombinant binding proteins and peptides
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
PT1071700E (en)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE19819846B4 (en)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalent antibody constructs
PT1914244E (en)	1999-04-09	2013-07-26	Kyowa Hakko Kirin Co Ltd	Method of modulating the activity of functional immune molecules
JP3871503B2 (en)	1999-08-30	2007-01-24	日本たばこ産業株式会社	Immune disease treatment
NZ521540A (en)	2000-04-11	2004-09-24	Genentech Inc	Multivalent antibodies and uses therefor
CA2785941C (en)	2000-10-06	2017-01-10	Kyowa Hakko Kirin Co., Ltd.	Antibody composition-producing cell
PT1583830E (en)	2003-01-07	2006-11-30	Symphogen As	Method for manufacturing recombinant polyclonal proteins
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
CA2625440C (en) *	2005-10-11	2023-06-13	Micromet Ag	Compositions comprising cross-species-specific antibodies and uses thereof
JP5082104B2 (en)	2006-03-23	2012-11-28	国立大学法人東北大学	Highly functional bispecific antibody
JP2010524851A (en)	2007-04-03	2010-07-22	マイクロメットアーゲー	Species-specific binding domains
KR101589759B1 (en)	2007-04-03	2016-01-29	암젠 리서치 (뮌헨) 게엠베하	Cross-species-specific cd3-epsilon binding domain
US10981998B2 (en) *	2008-10-01	2021-04-20	Amgen Research (Munich) Gmbh	Cross-species-specific single domain bispecific single chain antibody
EP2270053A1 (en)	2009-05-11	2011-01-05	U3 Pharma GmbH	Humanized AXL antibodies
UA117072C2 (en) *	2011-05-21	2018-06-11	Макродженікс, Інк.	CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
EP2832856A4 (en)	2012-03-29	2016-01-27	Chugai Pharmaceutical Co Ltd	Anti-lamp5 antibody and utilization thereof
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN113307873A (en)	2013-11-11	2021-08-27	中外制药株式会社	Antigen binding molecules comprising altered antibody variable regions
CN106459201A (en)	2014-05-28	2017-02-22	豪夫迈·罗氏有限公司	Antibodies binding to human and cynomolgus CD3 epsilon
TWI831044B (en)	2014-11-11	2024-02-01	日商中外製藥股份有限公司	Antigen-binding molecules, pharmaceutical compositions containing antigen-binding molecules, and methods of manufacturing and selecting antigen-binding molecules
EP4039710A3 (en)	2015-01-23	2022-10-19	Sanofi	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
IL267567B1 (en)	2016-12-22	2024-04-01	Daiichi Sankyo Co Ltd	Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody

2017
- 2017-12-21 IL IL267567A patent/IL267567B1/en unknown
- 2017-12-21 EP EP17884717.4A patent/EP3561057A4/en active Pending
- 2017-12-21 IL IL311136A patent/IL311136A/en unknown
- 2017-12-21 WO PCT/JP2017/046006 patent/WO2018117237A1/en active Application Filing
- 2017-12-21 JP JP2018558078A patent/JP7202185B2/en active Active
- 2017-12-21 SG SG10201912366YA patent/SG10201912366YA/en unknown
- 2017-12-21 CA CA3048174A patent/CA3048174A1/en active Pending
- 2017-12-21 KR KR1020197021178A patent/KR20190121294A/en active IP Right Grant
- 2017-12-21 BR BR112019012901-4A patent/BR112019012901A2/en unknown
- 2017-12-21 US US16/472,346 patent/US11618785B2/en active Active
- 2017-12-21 MX MX2019007347A patent/MX2019007347A/en unknown
- 2017-12-21 AU AU2017379382A patent/AU2017379382A1/en active Pending
- 2017-12-21 CN CN201780079717.1A patent/CN110431231B/en active Active
- 2017-12-22 TW TW106145218A patent/TW201829467A/en unknown
2019
- 2019-06-18 PH PH12019501387A patent/PH12019501387A1/en unknown
- 2019-07-19 CO CONC2019/0007823A patent/CO2019007823A2/en unknown
2022
- 2022-12-23 JP JP2022206884A patent/JP7478222B2/en active Active
2023
- 2023-04-03 US US18/194,987 patent/US20230287119A1/en active Pending

Also Published As

Publication number	Publication date
EP3561057A1 (en)	2019-10-30
AU2017379382A1 (en)	2019-07-11
TW201829467A (en)	2018-08-16
PH12019501387A1 (en)	2020-02-10
KR20190121294A (en)	2019-10-25
IL311136A (en)	2024-04-01
IL267567B1 (en)	2024-04-01
US20230287119A1 (en)	2023-09-14
CO2019007823A2 (en)	2019-10-09
WO2018117237A1 (en)	2018-06-28
RU2019122411A (en)	2021-01-25
US11618785B2 (en)	2023-04-04
US20190359712A1 (en)	2019-11-28
JPWO2018117237A1 (en)	2019-10-31
CN110431231A (en)	2019-11-08
CA3048174A1 (en)	2018-06-28
IL267567A (en)	2024-04-01
JP7202185B2 (en)	2023-01-11
BR112019012901A2 (en)	2020-01-07
JP7478222B2 (en)	2024-05-02
JP2023027374A (en)	2023-03-01
EP3561057A4 (en)	2020-09-16
CN110431231B (en)	2024-01-02
MX2019007347A (en)	2019-12-05
RU2019122411A3 (en)	2021-03-05

Publication	Publication Date	Title
ZA201905905B (en)	2022-05-25	Anti-gprc5d antibody and molecule comprising the antibody
IL268206A (en)	2019-09-26	Bcma-targeting antibody and use thereof
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL264011A (en)	2019-01-31	Antibodies against tim3 and uses thereof
SG10201912199XA (en)	2020-02-27	Anti-tim-3 antibodies and use thereof
IL274152B (en)	2021-02-28	Anti-galectin-9 antibodies and uses thereof
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-phf-tau antibodies and uses thereof
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and uses thereof
SG10201912366YA (en)	2020-02-27	Anti-cd3 antibody and molecules comprising the antibody
EP3541840C0 (en)	2023-12-27	Anti-hla-g antibodies and use thereof
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL263273A (en)	2018-12-31	Anti-gitr antibodies and uses thereof
IL269134A (en)	2019-11-28	Anti-par2 antibodies and uses thereof
HK1248721A1 (en)	2018-10-19	Antibody molecules and uses thereof
IL263242A (en)	2018-12-31	Cytosol-penetrating antibody and use thereof
IL262782B1 (en)	2023-04-01	Tl1a antibodies and uses thereof
ZA201807132B (en)	2021-05-26	Humanized anti-basigin antibodies and the use thereof
IL272476A (en)	2020-03-31	Anti-apelin antibodies and uses thereof
IL266049A (en)	2019-06-30	Anti-o1 antibodies and uses thereof
IL273157A (en)	2020-04-30	Axl-specific antibodies and uses thereof
AU2017271189A1 (en)	2019-01-24	Cytosol-penetrating antibody and use thereof
IL266082A (en)	2019-06-30	Anti-chikv antibodies and uses thereof
IL264417A (en)	2019-02-28	Anti-o2 antibodies and uses thereof